secwatch.observer — SEC 8-K summary
======================================

Issuer:     aTYR PHARMA INC (ATYR)
CIK:        0001339970
Form:       8-K
Filed at:   2023-05-09T23:59:59+00:00
Accession:  0000950170-23-019633
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

aTyr Pharma reports Q1 2023 cash of $117.6M; Phase 3 sarcoidosis trial enrolling
--------------------------------------------------------------------------------

- Cash, equivalents and investments of $117.6M as of March 31, 2023; $48.1M net from February stock offering.
- Phase 3 EFZO-FIT study of efzofitimod in pulmonary sarcoidosis enrolling in U.S., Europe and Japan; up to 264 subjects.
- Phase 2 proof-of-concept study in SSc-ILD expected to initiate Q3 2023; 25 patients, multiple U.S. centers.
- R&D expenses $9.4M and G&A expenses $3.4M for Q1 2023; cash runway projected into 2026.
- Multiple efzofitimod presentations planned at ATS 2023 International Conference May 19-24.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1339970/000095017023019633/0000950170-23-019633-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1339970/000095017023019633/life-20230509.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-019633

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer